The SAGITTARIUS Trial: Adjuvant Therapy Optimization
Spain is a primary participant in the SAGITTARIUS trial, a randomized Phase III study nearing its primary completion in early 2026.
Objective: The trial aims to show that adjuvant therapy (post-surgery treatment) guided by liquid biopsy improves outcomes for Stage II and Stage III colon cancer patients.
Participating Sites: Several major Spanish institutions, including Hospital del Mar (Barcelona) and INCLIVA (Valencia), are active locations for this study.
Technology: It utilizes the tumor-informed MRD assay Signatera™, allowing for precise detection of residual cancer DNA and more personalized treatment paths than conventional therapy.
2 Views